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ABSTRACT: New mixed cationic liposomes based on L-α-phosphatidylcholine and 
dihexadecylmethylhydroxyethylammonium bromide (DHDHAB) were designed to overcome the 
BBB crossing by using the intranasal route. Synthesis and self-assembly of DHDHAB were 
performed. A low critical association concentration (0.01 mM), good solubilization properties 
toward hydrophobic dye Orange OT and antimicrobial activity against gram-positive bacteria 
Staphylococcus aureus (MIC=7.8 μg.mL–1) and Bacillus cereus (MIC=7.8 μg.mL–1), low 
hemolytic activities against human red blood cells (less than 10%) were achieved. Conditions for 
preparation of cationic vesicle and mixed liposomes with excellent colloidal stability at room 
temperature were determined. The intranasal administration of rhodamine B-loaded cationic 
liposomes was shown to increase bioavailability into the brain in comparison to the intravenous 
injection. The cholinesterase reactivator, 2-PAM, was used as model drug for the loading in 
cationic liposomes. 2-PAM-loaded cationic liposomes displayed high encapsulation efficiency (~ 
90 %) and hydrodynamic diameter close to 100 nm. Intranasally administered 2-PAM-loaded 
cationic liposomes were effective against paraoxon-induced acetylcholinesterase inhibition in the 
brain. 2-PAM−loaded liposomes reactivated 12 ± 1% of brain acetylcholinesterase. This 
promising result opens the possibility to use marketed positively charged oximes in medical 
countermeasures against organophosphorus poisoning for reactivation of central 
acetylcholinesterase by implementing a non-invasive approach, via the "nose-brain" pathway. 
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1. Introduction  
Intranasal route remains one of the elective non-invasiveness routes for the treatment of brain 
diseases [1]. It is highly appealing in clinical settings due to rapid central action of drug. This 
expands drug efficiency in emergency treatment [2]. The nasal mucosa allows direct delivery of 
drugs to the brain bypassing the blood brain barrier (BBB). It avoids hepatic clearance and drug 
degradation by liver enzymes, and therefore, increases the effect of neurotherapy [3]. 
Applicability of intranasal route is limited by lipophilicity and molecular weight of drugs [4]. 
New formulations to maximize the concentration of drugs and new devices for intranasal 
administration have been developed [5]. To improve drug transfer to the brain and to prolong the 
residence time of drug in the nasal cavity, several strategies may be employed, namely the use of 
(i) permeation enhancers, muco-adhesive and heat sensitive gels, or (ii) nano-sized drug carriers. 
Colloidal nanosized carriers are especially important for brain delivery and targeting of drugs for 
treatment of neurodegenerative diseases [6]. Intranasal delivery to the brain by using nanosized 
particles can be carried out for small molecules, as well as for proteins, hormones, vaccines, 
DNA, etc [7-10]. The main strategy to improve drug delivery to the brain by intranasal 
administration is the modification of nanoparticles by absorption and permeation enhancers. For 
that purpose, surfactants, bile salts, cyclodextrins, derivatives of chitosan, arginine, lactoferrin, 
have already been proposed [11-16]. Liposomes are well-known universal nano-carriers. Their 
surface can be easily modified to provide them with multiple functions [17]. This has already 
been demonstrated for improvement of intranasal delivery [18] of rivastigmine [19,20], 
donepezil [21], zolmitriptan [22].  
The present work was aimed at using intranasal drug delivery as an alternative route to crossing 
of the BBB by using cationic liposomes as drug carriers. Cationic liposomes usually consist of 
natural neutral phospholipids and positively charged lipids [23]. Cationic liposomes deserve 
attention and further development since the ability of nanoparticles to penetrate the nasal mucus 
is obviously dependent not only on the size, but also, primarily, on the surface charge of particles 
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[24]. In addition, the positive charge of liposomes plays an important role in the in vitro 
processes of interaction with cells epithelium [25] and as a mucosal adjuvant [8,26]. We applied 
the cationic liposome intranasal drug delivery approach in the treatment of organophosphorus 
poisoning. Organophosphorus agents (OPs) are highly toxic chemicals used as pesticides; some 
of them are banned chemical warfare agents. OPs represent a global chemical threat for both 
armed forces and civilian populations [27]. The acute toxicity of OPs results from inhibition of 
acetylcholinesterase (AChE). Acute poisoning causes death due to respiratory failure, seizures 
and irreversible brain damage. The current post-exposure treatment is to administer a 
combination of an AChE reactivator, atropine as an anticholinergic drug, and an anticonvulsant 
to prevent irreversible brain damage [27,28]. However, current AChE reactivators (quaternary 
oximes) are unable to reactivate phosphylated AChE in the central nervous system because they 
do not cross significantly the BBB [29]. Different strategies have been implemented for allowing 
these reactivators to cross the BBB [30]. In particular, non-quaternary oximes capable of 
crossing the BBB were synthesized. However, none of newly synthesized molecules has been 
developed so far [31,32]. New trends have emerged with the development of nanotechnology 
and new delivery systems, making quaternary oximes capable of crossing the BBB [33-35]. The 
intranasal route has also been successfully tested for administration of drugs against OP 
poisoning. For example, intranasal midazolam led to cessation of soman-induced seizures [36]. 
Intranasal administration of oximes has been considered as an alternative way for bypassing the 
BBB. Indeed, intranasal administration of obidoxime contributed to a reduction of brain damage 
and death of rats after poisoning by paraoxon [37]. Also, aerosolized butyrylcholinesterase, as a 
bioscavenger, was successful for protection of macaque lungs against volatile OPs [38]; rapid 
intranasal delivery of enzymes to the brain indicates that this route could be used for protection 
of CNS against toxicants [39], including OPs. Our present results validate the intranasal brain 
delivery approach using cationic liposome as drug carriers. 
2. Materials and methods 
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2.1. Chemicals. Dihexadecyldimethylammonium bromide (DHDAB, 97%, Sigma-Aldrich), 
Tween® 80 (Polysorbate 80) (BioXtra, Sigma-Aldrich, product of France), L-α-
phosphatidylcholine (Soy, 95%, Avanti polar lipids), Phospholipon® 80 and Lipoid® S75, 75% 
soybean phosphatidylcholine were gifts from Lipoid GmbH (Ludwigshafen, Germany), 1-(o-
Tolylazo)-2-naphthol (75%, Orange OT, Aldrich, USA), pyrene (99%, Sigma, Switzerland), 
Pyridine-2-aldoxime methochloride (2-PAM chloride, Pralidoxime chloride) (≥ 97 %, Sigma-
Aldrich, product of China). Dihexadecylmethylhydroxyethylammonium bromide (DHDHAB) 
was synthesized as described in Supplementary material. Ultra-purified water (18.2 MΩcm 
resistivity at 25°C) was produced from Direct-Q 5 UV equipment (Millipore S.A.S. 67120 
Molsheim-France). All reagents were used without further treatment. DHDAB and DHDHAB 
are insoluble in water at room temperature. Their solutions were prepared by heating (up to 60 
ºC) in water without sonication or other energy except a manual mixing. Stable dispersions of 
surfactants were observed during cooling to room temperature (25 ºC). Stock solutions prepared 
at the concentration 10 mM were subsequently diluted with pure water to final working 
solutions.  
2.2. Fluorescence. Fluorescence spectra of pyrene (1×10-6 M) in water solutions of cationic 
surfactants were recorded at 35°C on a Varian Cary Eclipse spectrofluorimeter (Varian, Inc., 
California, USA) with excited wavelengths for pyrene at 335 nm using 1 cm path length quartz 
cuvettes. Emission spectra were recorded in the 350-500 nm range. The fluorescence anisotropy 
of 1,6-diphenyl-1,3,5-hexatriene (DPH) was measured on a Cary Eclipse (spectrometer (Varian, 
Inc., California, USA)) equipped with filter polarizers. DPH were excited at 361 nm, and the 
fluorescence intensity was measured at 450 nm. The embedded software automatically 
determined the correction factor and anisotropy value. A quartz cell of 1 cm path length was 
used for all fluorescence measurements. Measurements were performed in thermostated cell at 
35°C. A fixed concentration of 0.175 mM of fluorescence probe DPH was used. 
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2.3. Surface Tension. Surface tension measurements were carried out using several methods: i) 
the du Nouy ring detachment method (Kruss K6 Tensiometer, Hamburg, Germany). Briefly, the 
planar and spherical platinum ring was placed parallel to the air/solvent interface ii) the 
Wilhelmy plate method (Kruss K9 Tensiometer, Hamburg, Germany). The platinum plate was 
wetted to a set depth. A contact angle θ of 0° (cos θ = 1) with liquids was formed. The surface 
tension was calculated from the measured force. Between two surface tension measurements, the 
platinum ring and the platinum plate were cleaned with Ultra-purified water, then soaked in 
ethanol for 5–7 min, rinsed again with Ultra-purified water, and finally flame-dried; iii) the 
bubble pressure method. In this method air gas bubble was blown at constant rate through a 
capillary tube submerged into the surfactant solutions. The surface tension was calculated by the 
Laplace equation (∆Pmax = 2γ/r, where γ is the surface tension, and r is the capillary tip radius, 
using the measured maximum pressure difference ∆Pmax; iv) the drop weight (stalagmometric) 
method [40]. For this purpose, several drops of liquid leaked out of the glass capillary of the 
stalagmometer were weighed. The surface tension was determined from the number of drops 
leaking out; v) The pendant drop shape analysis technique [41, 42] is one of the most accurate 
methods to measure surface tension; it has many advantages over other methods [43, 44]. The 
surface tension was measured with a DSA 30 (Kruss tensiometer) using a 2.5 mL syringe with a 
fitted steel capillary of 1.84 mm outer radius. The DSA 30 tensiometer allows recording of the 
drop shape with a built-in digital video camera. The theoretical drop shape determined from the 
Young–Laplace equation was fitted to experimental drop profiles. The measured surface tension 
corresponded to the best fit. Temperature was kept at 35 ± 0.2°C during all experiments.  
2.4. Atomic force microscopy. An atomic force microscope (MultiMode V, USA) was used to 
reveal the morphology of the samples. RTESP cantilevers (Veeco, USA) with silicone tips were 
used in all measurements. The scanning rate was 1 Hz used to eliminate external distortions. 
Droplets of aqueous dispersions of the samples were carefully placed on mica surface. The AFM 
imaging was performed after water evaporation. 
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2.5. Small-angle neutron scattering. SANS measurements on DHDHAB solutions were 
performed on the Yellow Submarine instrument operating at the Budapest Research Reactor 
[45]. The surfactant was dissolved in D2O at concentrations 0.6 and 1.21 mg/ml, filled in planar 
quartz cells of 2 mm path length, and measured at 37± 0.5°C, over a q-range of 0.08 – 3 nm-1. 
The scattering curves were modeled by form factors of unilamellar vesicles, using the software 
SasView. 
2.6. Solubilization study. Solubilization study of the dye (Orange OT) was performed by adding 
an excess of crystalline Orange OT to the cationic surfactant solutions. These solutions were 
allowed to equilibrate for about 48 h at 35°C, followed by filtration, and the absorbance was 
measured at 495 nm using a spectrophotometer Specord 250 Plus (Analytik Jena AG, Germany). 
Quartz cuvettes (1 cm cell path) containing sample were used. Solubilization capacity of 
associates (S), which corresponds to the number of moles of dye solubilized per mole of 
surfactant was determined according to equation 1 [46,47] 
 lBS ext    (1) 
where В is the slope of dye absorbance as a function of surfactant concentration above CAC and 
εext the extinction coefficient of Orange OT (εext = 18720 M-1 cm-1). 
2.7. Antibacterial and antifungal activity. In vitro antibacterial and antifungal activities of the 
cationic surfactant were evaluated against pathogenic representatives of gram-positive and gram-
negative bacteria and fungi. Minimal inhibitory concentrations (MICs) were estimated by 
conventional dilution methods for bacteria and fungi [48]. The antibacterial and antifungal 
assays were performed in Hottinger broth (HiMe-dia Laboratories Pvt. Ltd Mumbai, India) and 
Sabouraud dextrose broth (HiMedia Laboratories Pvt. Ltd Mumbai, India) (bacteria 3 × 105 
cfu/ml and yeast 2 × 104 cfu/ml). The components of Hottinger broth (Lactalbumin hydrolysate 
(10 g), Peptone (10 g), NaCl (5 g)) were dissolved in one liter of distilled water, autoclaved for 
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20 min at 121°C. The pH was adjusted to 7.2 prior to autoclaving. The components of Sabouraud 
dextrose (Peptone (10 g), glucose (40 g)) were dissolved in one liter of distilled water, 
autoclaved for15 min at 121°C. The pH was adjusted to 5.6 prior to autoclaving. 
2.8. Hemolytic activity assay. The toxicity of cationic surfactant was tested for their hemolytic 
activities against human red blood cells (hRBC). Fresh hRBC collected from heparinized blood 
were rinsed 3 times with 35 mM phosphate buffer/0.15 M NaCl, pH 7.3 by centrifugation for 10 
min at 800 g and re-suspended in PBS. Test compound dissolved in PBS (concentrations 0.98–
500 μg/ml) were then added to 0.5 mL of a stock solution of hRBC in PBS to reach a final 
volume of 5 mL (final erythrocyte concentration was 10% v/v). The resulting suspension was 
incubated under stirring for 1 h at 37°C. The samples were then centrifuged at 2000 rpm for 10 
min. Release of hemoglobin from hRBC was monitored by measuring the supernatant 
absorbance at 540 nm. Controls for zero hemolysis (blank) and 100% hemolysis consisted of 
hRBC suspended in PBS and distilled water, respectively. 
2.9. Preparation of cationic DHDHAB vesicles and mixed cationic liposomes. L-α-
phosphatidylcholine and cationic surfactants (7% w/w) were dissolved in 2 ml of ethanol. The 
homogeneous solution was kept in a water bath at 60°C until alcohol evaporation to obtain a thin 
lipid film. Ultra-purified water (Milli-Q, Direct-Q5 UV) or saline (0.9%) was pre-heated to 60°C 
and added to rehydrate the lipids at 60°C in the absence or presence of 2-PAM (0.35% w/w). The 
solution was stirred under magnetic stirring (750 rpm) (Heidolph, Germany) for 30 min at the 
same temperature. Then the solution was kept for 1.5 hours in a water bath at 37°C. The 
multilamellar liposomes were extruded 20 times by passage through a polycarbonate membrane 
of 100 nm pore size (Mini-Extruder Extrusion Technique, Avanti Polar Lipids, Inc.). For 
preparation of cationic vesicles of DHDHAB at concentration up to ca. 1.0 mM the same process 
was performed. For the loading of liposomes with rhodamine B, the same method was used by 
replacing 2-PAM with rhodamine B (0.01% w/w). 
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2.10. Morphology and particle size analysis. The mean particle size, zeta potential and 
polydispersity index of nanoparticles were determined by dynamic light scattering (DLS) 
measurements, using the Malvern Instrument Zetasizer Nano (Worcestershire, UK) at neutral pH 
(close to 7). Measured autocorrelation functions were analyzed by Malvern DTS software, 
applying the second-order cumulant expansion methods. The effective hydrodynamic radius (RH) 
was calculated according to the Einstein-Stokes equation D=kBT/6πηRH, where D is the diffusion 
coefficient, kB the Boltzmann constant, T the absolute temperature, and η the viscosity. The 
diffusion coefficient was measured at least three times for each sample. Five measurements of 
electrophoretic mobilities on each sample were converted into zeta potential by using the 
Smoluchowski relationship [49]: ζ=μη/ε, where ζ is the zeta potential, η the dynamic viscosity of 
the fluid, μ the particle mobility and ε the dielectric constant. All samples were diluted with 
ultra-purified water to suitable concentration and analyzed in triplicate. Analysis of the optimal 
formulation was performed by fluorescence microscopy (Leica DM IRBE/Leica TCS SP2) to 
confirm the presence of liposomes, to verify the shape of the particles, and the absence of 
aggregation.  
2.11. Encapsulation efficiency and loading capacity. Encapsulation efficiency (EE, %) and 
loading capacity (LC, %) were assessed for samples containing 2-PAM and Rhodamine B. These 
parameters were determined indirectly by filtration/centrifugation technique, measuring free 2-
PAM (non-encapsulated) by spectrophotometry. A volume of 0.5 mL of each 2-PAM-loaded 
cationic liposomes was placed in centrifugal filter devices Ultracel 100K (100.000 MWCO, 
Amicon Millipore Corporation, Bedford, Massachusetts) to separate lipid and aqueous phases 
and centrifuged at 10000 rpm, for 15 minutes (Eppendorf AG, Hamburg, Germany). For 
liposomes containing rhodamine B, the same method was used, 2-PAM was replaced by 
Rhodamine B. Free 2-PAM and Rhodamine B were quantified by UV absorbance using a 
Specord 250 Plus (Analytik Jena AG, Germany) at 294 nm for 2-PAM (the extinction coefficient 
of 2-PAM at 294 nm is 11962 M-1.cm-1 in 0.025 M phosphate buffer at pH = 7.4) and at 555 nm 
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for Rhodamine B (the extinction coefficient of Rhodamine B at 555 nm is 92330 M-1.cm-1 in 
0.0025 M phosphate buffer at pH = 7.4) The parameters were calculated against appropriate 
calibration curve, using the following equation [34]: 
%100
2
22
(%) 


PAMofamountTotal
PAMFreePAMofamountTotal
EE  (2) 
%100
22
(%) 


lipidofamountTotal
PAMFreePAMofamountTotal
LC  (3) 
2.12. In vitro 2-PAM release profile. The monitoring of 2-PAM release from cationic 
liposomes was performed using the dialysis bag diffusion method. Dialysis bags retain liposomes 
and allow the released 2-PAM to diffuse into the dissolution medium. The bags were soaked in 
Milli-Q water for 12 h before use. One milliliter of cationic liposomes was poured into the 
dialysis bag and the two ends were sealed with clamps. The bags were then placed in a vessel 
containing 200 mL of 0.025 M sodium phosphate buffer pH 7.4, the receiving phase. The vessel 
was placed in a thermostatic shaker (New Brunswick, USA), at 37ºC, under a stirring rate of 150 
rpm. At predetermined time intervals, 1 mL samples were withdrawn, and and their absorbance 
at 294 nm was measured using a Specord 250 Plus (Analytik Jena AG, Germany). All samples 
were analyzed in triplicate. 
2.13. Histology Analysis of Brain. All experiments involving animals were performed in 
accordance with the guidelines set forth by the European Communities Council Directive of 
November 24, 1986 (86/609/EEC) and the protocol of experiments approved by the Animal Care 
and Use Committee of Kazan Federal University. Wistar rats of both sexes were purchased from 
the Laboratory Animal Breeding Facility (Branch of Shemyakin-Ovchinnikov Institute of 
Bioorganic Chemistry, Puschino, Moscow Region, Russia) and were allowed to acclimate to 
their environment in the vivarium for at least 1 week before experiments. Animals were kept in 
sawdust-lined plastic cages in a well-ventilated room at 20–22 °C in a 12-h light/dark cycle, 
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60−70% relative humidity and given ad libitum access to food and water. Free rhodamine B or 
rhodamine B loaded cationic liposomes were intravenously injected or administrated intranasally 
to Wistar rats at the same dose, 0.5 mg/kg. Non-treated animals were used as controls with 
respect to background fluorescence. 45 minutes after injection, animals were anesthetized, their 
brain was isolated and stored at −80°C. Frozen tissue was moved to a −20°C freezer 24 h before 
slicing. Tissues were sliced into 10 μm sections using Sakura Tissuestek Cryo3 microtome 
(Sakura Finetek, Torrance, CA). The tissue sections were examined with a Leica TCS SP5 
confocal microscope (Leica, Germany) using a cyanine 3 (CY3) filter (excitation wavelength 
550 nm and emission at 570 nm). Microphotographs were taken using the Leica LAS AF 
program. 
2.14. Measurement of in vivo brain AChE inhibition and reactivation level. For in vivo brain 
AChE inhibition assay rats were poisoned by 0.8×LD50 of POX (600 μg/kg, i.p.). Whole brains 
were collected 1 h after POX administration and frozen in liquid nitrogen. Whole brains of rat 
control group were collected 1h after intraperitoneal (i.p.) injection of physiological saline. 
Thereafter, AChE activity of brain homogenates was analyzed. The mean brain AChE activity of 
poisoned animals was compared with mean brain AChE activity of control group. 
For in vivo brain AChE reactivation assay, 1 h after poisoning by 0.8×LD50 of POX, 2-PAM in 
cationic liposomes was administrated intranasally at the dose 7 mg/kg. Whole brains were then 
collected 1h after administration of 2-PAM- cationic liposomes and frozen in liquid nitrogen. 
The mean activity of brain AChE after intranasal administration of 2-PAM-cationic liposomes 
was compared to the mean brain AChE activity of poisoned group. 
Whole brain homogenates were prepared in a Potter homogenizer with 0.05 M Tris-HCl, 1 % 
Triton X-100, 1 M NaCl, 2 mM EDTA; pH 7.0 (1 volume of brain for 2 volumes of buffer) at 
4°C. The homogenates were centrifuged (10,000 rev/min, at 4ºC) for 10 minutes using 
Eppendorf 5430R centrifuge with FA-45-30-11 rotor (Eppendorf AG, Hamburg, Germany).  
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For AChE activity assay, 50µl supernatant was incubated with 5µl of tetra-isopropyl 
pyrophosphoramide (iso-OMPA) – as a butyrylcholinesterase specific inhibitor - in final 
concentration 0.1 mM, for 30 minutes. Then, AChE-catalyzed hydrolysis reaction of substrate 
was started by adding of 10 µl of acetylthiocholine iodide (final concentration 1 mМ). After 10, 
20 or 30 min samples reaction with substrate at 25°C, reactions were stopped by adding the 
carbamylating agent neostigmine (0.1 mM). Samples were diluted in 50 mM phosphate buffer 
(pH 8.0) and DTNB (0.1 mM) was added. AChE activity was measured according to the Ellman 
method37 by determining the production of yellow 5-thio-2-nitro-benzoate anion, resulting from 
reduction of DTNB by thiocholine (the product of substrate hydrolysis) at 412 nm by 
spectrophotometry (PerkinElmer λ25). The amount of thiocholine produced during 20 min 
(10th–30th min) was calculated. Sample without substrate was used as a blank. All 
measurements for each sample were done in triplicate. AChE activity was expressed in relation 
to the amount of total protein, which was determined by the Bradford method. Data were 
analyzed using Origin 8 software and expressed as the mean ± SEM. Statistical analysis was 
performed using the Mann-Whitney test. P< 0.05 were considered statistically significant. 
3. Results and discussion 
In the present work, two cationic surfactants dihexadecyldimethylammonium bromide 
(DHDAB) and dihexadecylmethylhydroxyethylammonium bromide (DHDHAB) (Fig. 1) were 
used for modification of liposomes. Our interest focused on the properties of cationic surfactants 
with double, long-chains due to the fact that these surfactants are synthetic vesicle-forming 
amphiphiles capable of self-assembling spontaneously as giant uni-lamellar vesicles [50-52]. 
Properties and dissolution of surfactants strongly depend on temperature, the chain length of 
alkyl radicals and the type of counter ions [53]. Not enough attention has been paid to the 
influence of structure of polar head-group of such cationic surfactants on their properties. In this 
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work main attention is paid to the effect of hydroxyl group in polar head-group of cationic 
surfactants with double, hexadecyl chains.  
 
Figure 1. Structures of cationic surfactants dihexadecyldimethylammonium bromide (DHDAB) 
and dihexadecylmethylhydroxyethylammonium bromide (DHDHAB), hydrophobic dye (Orange 
OT) and fluorophore probes (Pyrene, Rhodamine B) and AChE reactivator (2-PAM). 
3.1. Self-assembly and solubilization properties of cationic surfactants  
Self-assembly of cationic surfactants was investigated by fluorescence, tensiometry, 
spectrophotometry and dynamic light scattering at 35°C. 
 
Figure 2. Dependence of the intensity ratio (I1/I3) of the first and third peaks of pyrene (a), 
optical density of Orange OT (b) on concentrations of DHDAB (1) and DHDHAB (2) and 
surface tension (c) on concentrations DHDHAB, using different techniques: Du Nouy Ring 
method with fresh solutions (1), the same method with solutions after 1 week storage (2); the 
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Wilhelmy plate method (3), the bubble pressure method (4), the drop weight (stalagmometric) 
method (5), the pendant drop shape analysis (6); Cpyrene = 1×10
-6 M, T = 35°C. 
To determine the critical association concentration (CAC) of DHDAB and DHDHAB a 
technique with pyrene as fluorophore probe was used [54,55], which involved the analysis of the 
intensity of pyrene peaks at 373 nm (I1) and 384 nm (I3) (Fig 1S, Supplementary material). The 
ratio of the intensity of the first and third peaks (I1/I3) indicates the effect of microenvironmental 
polarity on pyrene fluorescence. The value (I1/I3) is decreasing with increasing surfactant 
concentration (Fig. 2a). This indicates the onset of surfactant aggregation and transfer of pyrene 
from the water phase to a nonpolar area of aggregates. After that value (I1/I3) remains 
unchanged. The obtained CACs for DHDAB and DHDHAB are similar, close to 0.025 mM.  
The formation of associates at low concentrations was confirmed by solubilization of 
hydrophobic dye (Orange OT) (Fig 2b). The increase in optical density of Orange OT in cationic 
surfactant solutions was observed above the CAC1. This is due to solubilization of the dye in the 
hydrophobic area of surfactants associates. It should be noted that such kind of surfactants 
(dioctadecyldimethylammonium bromide) were also shown to be effective solubilizer /or 
colloidal stabilizer for the hydrophobic drug miconazole [56]. The CAC1s for both DHDAB and 
DHDHAB are 0.01 mM, which is close to the CAC1s determined by fluorescence. The 
solubilization capacity, determined by equation 1, is 0.06 and 0.22 for DHDAB and for 
DHDHAB, respectively. These values are 4 and 14 times, respectively, higher than the 
solubilization capacity of the classical surfactant CTAB. 
Measurements of surface activity of DHDHAB at air-water interface using different techniques 
are presented in Fig. 2c. The decrease in surface tension (γ, mN.m-1) is observed with increasing 
the surfactant concentration. It can be seen in Fig. 2c that the different techniques showed 
consistent results: the surface tension is reduced only at high concentration (close to 10 mM). A 
similar effect was observed for dioctadecyldimethylammonium bromide (DODAB) by Feitosa 
and Brown [57]. Critical concentration attributed to spontaneous formation of vesicles which 
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was detected by optical spectroscopy and fluorescence at lower concentrations was not observed 
by tensiometry. It appears that physical and morphological properties, and CAC of double-tail 
cationic surfactant depend not only on concentration, solvent conditions, and the presence of 
additives, but also the sample preparation protocol and the history of temperature treatment 
[58,59]. For example, the CAC of DHDAB determined by Tucker was 0.01 mM [60] However, 
the CAC value found by Nagarajan is lower (0.0034 mM) [61]. Lower CAC (close to 0.0001 
mM) were also determined using a linear relationship between log(CAC) and the number of 
carbon atoms in the dialkyl chain (n) [62] and CAC of DDAB [63-65]. These strongly different 
aggregation concentrations, observed by tensiometry and fluorescence probes can be explained 
by the difference of the utilized measurement techniques. The majority of techniques for 
measurement of adsorption micelle-forming surfactants at the water-air surface are not sensitive 
enough for adsorption of surfactants at the very low concentrations, when the surfactant 
molecules do not cover the entire surface. Indeed, unlike classical surfactants, the two alkyl-
chain surfactants diluted from mother liquors to low concentrations likely form stable 
spontaneous vesicles rather than individual surfactant molecules capable to adsorb at the 
interface. Importantly, unlike fluorimetry and dye solubilization, the surface tension 
measurement method is aimed at the examination of the surface activity of amphiphilic 
molecules rather than bulk aggregation. It detects well the formation of a surfactant monolayer 
on the water-air interface, while the occurrence of the water-surrounded surfactant bilayers or 
vesicles in the bulk of the solution does not necessarily show up as surface effect. Therefore, 
surface tension remains insensitive to the presence of vesicles, while the light scattering and dye 
solubilization methods detect precisely aggregates in the bulk that are sufficiently large, or 
possess distinct hydrophobic compartment. 
Size (hydrodynamic diameter) of DHDAB and DHDHAB associates was determined by 
dynamic light scattering at different surfactant concentrations. The size of nanoparticles about 
500 nm was observed for DHDAB concentration ≥CAC1 (Fig 2S). The zeta potential of particles 
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was + 60±2 mV, the polydispersity index was 0.5±0.02. All parameters did not change with 
increasing DHDAB concentration (Table 1S). In the case of DHDHAB, two different size 
distribution patterns were observed depending on the surfactant concentration. Population of 200 
nm occurs at concentrations ≥ CAC1, while two populations, 30 nm and 200 nm were observed 
at DHDHAB concentrations ≥ 18 mM (Fig. 3S, Table 1S). The polydispersity index increased 
from 0.3 to 0.5 with increasing concentration. The fluorescence anisotropy of 1,6-
diphenylhexatriene (DPH) was investigated for determination of the morphology of DHDHAB 
associates. In Fig 4S in Supplementary material, it can be seen that the fluorescence anisotropy 
of DPH is ≥0.1 in the concentration range of DHDHAB 0.01-0.03 mM. These values are in good 
agreement with spontaneous formation of vesicles. The anisotropy fluorescence of DPH is ≤0.1 
at higher concentrations of DHDHAB (above 1mM). This value of anisotropy indicates the 
formation of micellar associates at high concentrations. 
The structure of the DHDHAB associates was further analyzed by small-angle neutron scattering 
(SANS) [66]. The scattering curves show the characteristic shape of flat structures (within the 
resolution range of the observation window 0.1-10 nm), which can be identified as large 
unilamellar vesicles (Fig. 3).  
 
Figure 3. SANS scattering curves of dihexadecylmethylhydroxyethylammonium bromide at two 
different concentrations in D2O at T = 37ºC: CDHDHAB = 2 mM (1), 1 mM (2).  
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Small micelles, even if present, could not be detected due to their much weaker scattering signal. 
In model fitting, the vesicle diameter and polydispersity was fixed at values 60 nm and 0.2, 
provided by light scattering, since the whole vesicle shape cannot be resolved at the given 
resolution limit. Model fitting gave membrane thickness of 4.14±0.08 nm and 4.13±0.5 nm for 1 
and 2 mM DHDHAB solutions, respectively, which are in accord with the size of the surfactant 
molecule. The above presented results show that addition of hydroxyl group to the structure of 
the head group of surfactants with double hexyl chains can make a significant contribution both 
to self-assembly and solubilization properties of the investigated cationic surfactant 
dihexadecylmethylhydroxyethylammonium bromide. 
3.2. Antimicrobial activity and hemolysis of DHDHAB  
Determination of cytotoxicity or cell viability remains the most frequent test used as proof of 
biocompatibility of nanoparticles. It was reported that cytotoxicity of cationic liposomes 
composed of phosphatidylcholines and dialkyldimethylammonium bromide is increased with 
increasing surfactant concentration and their hydrophobic chain lengths [67]. Such kind of 
nanoformulations was recommended for topical therapy [68]. Cationic surfactants with double, 
long-chains exhibited antimicrobial properties [69]. It was confirmed that the determining factor 
of the antifungal action of cationic surfactants is not cell lysis, but a change in the cell surface 
from negative to positive charge [70]. Antimicrobial activity of DHDHAB surfactant is 
presented in Table 1. It is obvious that the DHDHAB surfactant is very effective against gram-
positive bacteria Staphylococcus aureus (MIC=7.8 μg.mL–1) and Bacillus cereus (MIC=7.8 
μg.mL–1). In order to provide evidence of biocompatibility of cationic surfactant formulations we 
investigated their action on hemolysis. The hemolytic action of DHDHAB surfactant on human 
erythrocytes is less than 10% in the concentration range used for liposomes surface modification. 
 
Table 1.  
Antimicrobial activity (mg/L) and haemolysis of human red blood cells (%)a 
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Compound 
Bacteriostatic and fungistatic activity (MIC), μg.mL–1 C / Hb 
 Sa Bc E ci Pa Tm An Ca 
DHDHAB 7.8±0.6 7.8±0.6 >500 >500 >500 >500 >500 7.8 / 5.5 
 
Bactericidal and fungicidal activity, μg.mL–1 
31.3±2.8 >500 31.3±2.7 250±22 >500 >500 >500 
aThe tests were performed in duplicate and repeated twice; bС is the concentration of DHDHAB 
(μg.mL–1); H is haemolysis of human red blood cells (%). 
Sa, Staphylococcus aureus АТСС 209P; Bс, Bacillus cereus АТСС 8035; Pa, Pseudomonas 
aeruginosa АТСС 9027; Ec, Escherichia coli CDC F-50; An, Aspergillus niger BKMF-1119; 
Tm, Trichophyton mentagrophytes var. gypseum 1773; Ca, Candida albicans BKПГу-401/NCTC 
885-653.  
 
3.3. Preparation and characterization cationic DHDHAB vesicles and cationic mixed 
Ph/DHDHAB liposomes  
Initially, the liposome preparation technique was developed using natural, commercially 
available and widely used phospholipids (Phospholipon 80, Lipoid S 75 and L-α-
phoshatidylcholine (95%) and nonionic surfactant (Tween 80). The macroscopic appearance of 
each sample indicated that the formation of homogeneous multilamellar liposomes occurs only 
from L-α-phoshatidylcholine (Ph). We continued to improve the liposome solution by varying 
the concentration of the different components, their ratio, using several techniques (ultrasonic 
bath, ultrasonic probe and extrusion). The physicochemical characterizations of nano-
formulations are presented in Table 2. The same liposome preparation technique was used for the 
preparation of DHDHAB cationic vesicles. The morphology and size of prepared DHDHAB 
cationic vesicles were investigated by atomic force microscopy. Small nanoparticles of 
spherical-ellipsoidal shape were observed. Nanoparticle diameter is 50 nm and their elevation is 
about 1-2 nm (Fig. 4) AFM results are comparable with properties measured by DLS (Table 2, 
Fig. 5S). 
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Table 2.  
Hydrodynamic diameter (number, volume and intensity – averaged), polydispersity index (PdI) 
and Zeta potential (ZP) as a function of lipid structure, concentration and component ratio in 
different formulations, pH=7, t=25ºC. 
№ Formulation Ratio 
Ph/surf., wt% 
Loaded 
compound 
hydrodynamic diameter, nm PdI ZP, mV 
Number Volume Intensity   
1 Ph/Tween 99.5/0.5 - 68±2 91±2 122±1 0.25±0.01 -14±2 
2 DHDHAB 100 - 79±1 91±1 122±1 0.06±0.01 - 
3 Ph/DHDAB 99.5/0.5 - 79±3 91±3 122±6 0.23±0.02 +39±1 
4 Ph/DHDHAB 99.9/0.1 - 91±3 122±2 164±3 0.143±0.01 -1±0.3 
5 Ph/DHDHAB 99.75/0.25 - 80±3 91±3 122±6 0.16±0.03 +15±2 
6 Ph/DHDHAB 99.5/0.5 - 91±3 106±2 122±6 0.1±0.03 +25±2 
7 Ph/DHDHAB 99/1 - 68±2 79±1 122±6 0.12±0.01 +32±1 
8 Ph/DHDHAB 95/5 - 79±1 106±2 164±3 0.16±0.02 +64±2 
9 Ph/DHDHAB 99.5/0.5 Rhod B 80±2 91±3 122±6 0.34±0.03 +24±2 
10 Ph/DHDHAB 99.5/0.5 2-PAM 80±2 91±3 142±2 0.2±0.03 +6±0.2 
The conversion to intensity, number and volume-averaged distribution highlights different sizes 
of extruded vesicles with lower polydispersity index (0.06). DHDHAB extruded vesicles are not 
ideally spherical in accordance with AFM data. The size of DHDHAB cationic vesicles does not 
change during six months and more. This indicates the high stability of samples. 
 
Figure 4. AFM image of DHDHAB cationic vesicles. 
Double-tail surfactants were used for the preparation of mixed Ph/surfactant cationic liposomes. 
They differ considerably in lipid composition and surface charge. It is well known that the 
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vesicle shape depends on membrane curvature and bending elasticity. Several experimental 
results indicate that various conditions (different physical stimuli and additives) can affect the 
vesicle shape [71-74]. Until now, a few examples have been established to evaluate the effect of 
a surfactant (varying in charge, length of carbon chain, structure of head group) on the properties 
of liposomes. There are a few examples showing that stability of cationic liposomes depends on 
the concentration and nature of cationic surfactants. It was shown that the adjuvantity of cationic 
liposomes also depends on the content of surfactant [75,76]. The addition of cationic surfactant 
(DHDAB and DHDHAB) did not provoke structural changes in liposomes morphology. The size 
of extruded cationic liposomes was close to extruded vesicles and their polydispersity was low 
(around 0.1). It was established that when cationic surfactants (DHDAB and DHDHAB) were 
used instead of a nonionic surfactant (Tween 80), the charge of mixed liposomes changed from 
negative (-14 mV) to positive (+36mV and +25 mV, respectively). Unlike Ph/Tween liposomes 
mixed cationic liposomes remain stable. An increase of the charge of cationic liposomes from -1 
mV to +64 mV is possible by increasing the concentration of cationic surfactant from 0.1% to 5 
% (w/w), respectively (form. № 4-8). The charge of mixed cationic Ph/DHDAB and 
Ph/DHDHAB liposomes is changed to -9mV and +6 mV respectively, in 6 months. The size of 
Ph/DHDAB liposomes decreased and polydispersity increased during the same time compared to 
Ph/DHDHAB liposomes. Likely, the addition of cationic surfactant (DHDAB) provoked 
structural changes in liposome morphology in course of time. Thus, Ph/DHDHAB liposomes 
were more stable during time.  
3.4. In vitro release studies and 2-PAM loading  
Cationic Ph/DHDHAB liposomes with composition 99.5/0.5 % (w/w) (form. №6) were chosen 
for encapsulation of pralidoxime chloride (2-PAM). The size of the 2-PAM-loaded liposomes 
was about 80 nm, the polydispersity index 0.2 ± 0.03, the zeta potential + 4 ± 2 mV. 2-PAM has 
a permanent positive charge, and in addition, at pH 7.4, about 50% of the oxime function is in 
oximate form. Thus, the decrease in zeta potential of cationic Ph/DHDHAB liposomes is likely 
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due to positively charged and zwitterionic properties of 2-PAM. Encapsulation efficiency of 2-
PAM, determined from equation 2, is rather high and equals almost 90%. Loading capacity of 2-
PAM, determined from equation 3, is 22.5%. The dialysis method was performed to study the 
release of 2-PAM in vitro conditions. The release of 2-PAM from aqueous solutions and 
liposomes are presented in Fig. 5.  
 
Figure 5. In vitro 2-PAM release from cationic Ph/DHDHAB liposomes using the dialysis bag 
method (n=3). 1- 2-PAM aqueous and 2- 2-PAM-liposomes solutions, phosphate-buffer (0.025 
M), рН=7.4, 37ºС.  
The release of 2-PAM (90%) from the cationic Ph/DHDHAB liposomes takes three hours. It is 
three times slower than in the case of an aqueous solution. 
3.5. Intranasal administration of the fluorescent-labeled cationic liposomes 
To confirm the uptake of cationic Ph/DHDHAB liposomes into the brain tissue, cerebral cortex 
slices were analyzed by fluorescence microscopy (Fig. 6). Free rhodamine B was used as control. 
Physico-chemical characteristics of cationic mixed Ph/DHDHAB liposomes with included 
fluorescent probe (Rhodamine B) are presented in Table 2 (form. № 9). Encapsulation of 
Rhodamine B did not change both size and charge of cationic liposomes. EE (%) and LC (%) 
parameters determined from equations 2 and 3 are 98±1% and 1.4±0.02%, respectively. In Fig. 6 
it is clearly seen that the greatest absorption of rhodamine B in brain occurs through the nasal 
route. 
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Figure 6. Section of cerebral cortex of rat treated with rhodamine B solution (A, C), treated with 
rhodamine B labeled cationic Ph/DHDHAB liposomes (B, D) by intravenous administration (A, 
B) and using intranasal route (C, D).  
3.6. Reactivation of Brain AChE in Vivo 
To test the in vivo efficacy of 2-PAM-loaded cationic Ph/DHDHAB liposomes against OPs, we 
used a rat model for OP toxicity using the organophosphate paraoxon (POX) as 
acetylcholinesterase inhibitor. After 1 h of poisoning by 0.8 × LD50 of POX (600 mg/kg, ip), 
brain samples were collected and AChE activity was analyzed. One hour after administration, 
this sub-lethal dose of POX (600 mg/kg, ip) resulted in 83.5 ± 4% inhibition of AChE in the 
brain (Figure 7). One hour after POX (600 mg/kg, ip), 2-PAM-loaded cationic liposomes were 
administered intranasally at the dose of 7 mg/kg. One hour after administration of 2-PAM-loaded 
cationic liposomes, activity of AChE was analyzed. It was previously found that intranasal 
administration of free 2-PAM (10 mg per animal) was ineffective in reducing paraoxon-mediated 
AChE inactivation in rat brain homogenates [37], whereas 2-PAM−liposomes reactivated 12 ± 
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1% of brain AChE (Figure 7). For substantial increase of AChE reactivation, more effective 
oximes could be used. However, gain in AChE reactivation level will certainly be obtained with 
2-PAM by optimizing cationic surfactant formulations.  
 
Figure 7. Determination of brain AChE reactivation level in vivo; mean AChE activity of brain 
homogenates was measured in a control group of rats (taken as 100%), after poisoning by 0.8 × 
LD50 of POX (6 mg/kg, ip) (A) and intranasal administration of 2-PAM-loaded cationic 
liposomes (B), dose of 2-PAM 7 mg/kg. Data are presented as mean ± SE. (n = 5). * p<0.05 
indicate significant difference by Mann–Whitney test. 
4. Conclusions 
The bioavailability of rhodamine B-loaded cationic liposomes to the brain when delivered by 
intranasal route was shown to be higher than when administered intravenously. 2-PAM-loaded 
cationic liposomes (the dose of 2-PAM was 7 mg/kg) intranasally administered to rat challenged 
with paraoxon (0.8 × LD50) were shown to reactivate central AChE (12%). This study provides 
evidence that reactivation of central AChE can be achieved by a non-invasive approach, i.e. to 
deliver oxime-loaded cationic liposomes to the brain via the "nose-brain" pathway. 
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